Metopimazine Sans Sucre, Édulcoré À L’aspartam Venipharm

Metopimazine, the active ingredient in Metopimazine Sans Sucre, Édulcoré À L’aspartam Venipharm, is a phenothiazine antiemetic presented as an oral tablet for oral use. It treats nausea and vomiting, including post‑operative nausea and vomiting, in adult patients.

GNH USA supplies Metopimazine Sans Sucre, Édulcoré À L’aspartam Venipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Metopimazine is a dopamine‑antagonist antiemetic used to control nausea and vomiting. - Nausea: reduces the sensation of nausea in various clinical settings. - Vomiting: helps prevent and control episodes of vomiting. - Post‑operative nausea and vomiting: lowers the incidence of nausea and vomiting after surgery.

Metopimazine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dry mouth: reduced salivation leading to a dry oral cavity. - Constipation: decreased bowel movements. - Blurred vision: temporary visual disturbances. - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Extrapyramidal symptoms: involuntary muscle movements or rigidity. - Neuroleptic malignant syndrome: rare, life‑threatening reaction with fever and muscle rigidity. - Severe hypotension: marked drop in blood pressure. - Cardiac arrhythmia: irregular heart rhythm. - Allergic reactions: rash, itching, or swelling. - Blood dyscrasias: abnormal blood cell counts.

Before prescribing Metopimazine, clinicians should consider several safety factors. - Renal or hepatic impairment: adjust use based on liver or kidney function. - Elderly patients: start with the lowest effective dose and monitor closely. - Known hypersensitivity: avoid if the patient has a documented allergy to phenothiazines. - Extrapyramidal monitoring: watch for signs of movement disorders during therapy. - Concomitant CNS depressants: use with caution as additive sedation may occur. - Store at below 25°C: keep in the original pack, protect from moisture.

Metopimazine can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Antipsychotics: may increase risk of extrapyramidal effects. - MAO inhibitors: can potentiate hypertensive reactions. - QT‑prolonging drugs: combined use may raise the risk of cardiac arrhythmias. - CNS depressants: additive sedation and respiratory depression. - Strong CYP2D6 inhibitors: may raise Metopimazine plasma levels.

Moderate Interactions (Monitor Closely): - Antihistamines: may enhance anticholinergic side effects. - Anticholinergic agents: increase risk of dry mouth and constipation. - Opioids: potential for enhanced nausea control but also increased sedation. - Alcohol: may intensify drowsiness and dizziness.